Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates

Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially Acinetobacter baumannii. Diazabicyclooctane (DBO) β-lactamase inhibitors, such as avibactam (AVI),...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Jose Cedano, Michelle Baez, Fernando Pasteran, Sabrina Daiana Montaña, Grace Ra, Venjaminne Fua, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramírez
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2022-07-01
סדרה:	Frontiers in Cellular and Infection Microbiology
נושאים:	Acinetobacter carbapenem-resistance zidebactam sulbactam DBOs synergy
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.918868/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!